Highlights

  • Nyrada shares rose 13.51% to AUD 0.63 during the afternoon session on 20 May 2026, following a positive oncology study update.
  • Xolatryp demonstrated anti-tumour activity both as a standalone therapy and in combination with doxorubicin.
  • Combination treatment achieved a 57% reduction in tumour Volume versus vehicle control.
  • The combination therapy delivered approximately 39% greater anti-tumour activity relative to doxorubicin alone.
  • Nyrada lodged a provisional Patent application covering Xolatryp as an anti-cancer agent.

Nyrada Inc (ASX:NYR) shares climbed 13.51% to AUD 0.63 during the afternoon session on 20 May 2026 after the biotechnology company released favourable preclinical oncology study results involving its lead drug candidate, Xolatryp. The stock has also recorded a substantial gain of approximately 472.73% over the past year, reflecting continued investor interest in the company’s clinical development pipeline and broader therapeutic potential of its TRPC ion channel technology.

The latest market reaction followed the release of data showing that Xolatryp demonstrated anti-tumour activity in a preclinical liver cancer model, both as a monotherapy and when used in combination with the chemotherapy drug doxorubicin. According to the company, the combination treatment produced the most significant reduction in tumour growth within the study.

Combination Therapy Delivered Greater Tumour Reduction

Nyrada stated that the study evaluated Xolatryp in a Huh7 cell-line derived rodent xenograft model of liver cancer, which is commonly used in preclinical tumour growth inhibition research.

The company tested four treatment groups:

  • vehicle control;
    • doxorubicin alone;
    • Xolatryp alone; and
    • a combination of doxorubicin with Xolatryp.

Tumour measurements were conducted every second day over a two-week period after treatment initiation.

According to the study results, the combination of Xolatryp and doxorubicin achieved the largest reduction in tumour volume, delivering a 57% reduction compared with vehicle control by Day 14.

By comparison, doxorubicin monotherapy produced a 41% reduction in tumour volume, while Xolatryp as a standalone therapy generated a 32% reduction relative to the control group.

The company said the combination treatment represented an approximately 39% improvement in anti-tumour activity relative to doxorubicin alone, which was considered consistent with an additive therapeutic effect.

The findings appear to have been received favourably by investors, particularly given doxorubicin’s established role as a widely used first-line chemotherapy treatment across multiple cancer types.

Early Tumour Reduction Observed in Combination Group

Nyrada also highlighted that tumour growth reduction in the combination treatment group was observed relatively early during the study period.

According to the company, statistically significant tumour reduction was detected as early as Day 4 in the doxorubicin plus Xolatryp group, with the reduction maintained through to the study endpoint.

Doxorubicin alone demonstrated significant tumour reduction from Day 6 onward, while Xolatryp monotherapy showed significant reductions beginning from Day 10.

The earlier onset observed in the combination group may support further investigation into the therapy’s broader oncology potential, particularly in settings where anthracycline chemotherapy agents remain standard treatment Options.

Why Doxorubicin Matters

Doxorubicin is a long-established anthracycline chemotherapy drug that has been used in oncology treatment since the 1970s.

The drug forms part of standard treatment regimens for multiple cancer indications, including liver cancer, breast cancer, lymphomas, leukemias, sarcomas and several solid tumours.

Nyrada noted that doxorubicin is frequently referred to as a “backbone drug” in oncology due to its broad use across cancer treatment programs.

The company’s latest study therefore focused on assessing whether Xolatryp could enhance the anti-tumour effects of an already established chemotherapy therapy while potentially supporting improved treatment outcomes.

Published scientific literature referenced by the company also points to the role of TRPC channels in cancer progression and multidrug resistance in hepatocellular carcinoma cells, supporting the rationale for evaluating Xolatryp in oncology applications.

Safety and Tolerability Findings

In addition to efficacy observations, the study also evaluated general animal health, body weight and cardiac biomarkers during the treatment period.

Nyrada stated that overall animal health remained broadly consistent with expectations for the model used in the study.

The company disclosed that two animals in the combination treatment group died prematurely due to tumour lysis syndrome (TLS), which is a recognised clinical condition associated with rapid tumour cell death causing metabolic disturbances.

According to the company, TLS is often linked with highly active anti-cancer therapies and can be managed clinically.

Nyrada also reported that animals receiving Xolatryp, both alone and in combination with doxorubicin, demonstrated a favourable trend in cardiac troponin I levels compared with doxorubicin monotherapy.

Cardiac troponin I is commonly used as a biomarker associated with heart injury, particularly relevant in patients receiving anthracycline chemotherapy treatments such as doxorubicin, which can carry cardiotoxicity risks.

Patent Application Lodged for Oncology Use

Alongside the preclinical data release, Nyrada confirmed that it has lodged a provisional patent application covering the use of Xolatryp as an anti-cancer agent.

The company said the filing complements its earlier allowed composition of matter patent application related to the drug candidate.

The patent application reflects Nyrada’s intention to continue expanding the intellectual property position surrounding Xolatryp as the company investigates broader therapeutic applications beyond its current cardiovascular program.

Further Studies Planned

Nyrada indicated that the latest findings support continued preclinical evaluation of Xolatryp across additional tumour types where anthracycline-based therapies remain part of standard treatment protocols.

Future work is also expected to assess Xolatryp in combination with other clinically relevant anti-cancer agents.

In addition, the company plans to explore systemic dosing strategies designed to optimise anti-tumour efficacy while maintaining tolerability.

A separate preclinical cardiomyopathy study is also underway to further evaluate whether Xolatryp may help mitigate cardiac injury associated with doxorubicin treatment.

The company stated that this work could support development of Xolatryp as a differentiated adjunct therapy alongside anthracycline chemotherapy.

CEO Comments on Study Findings

Nyrada Managing Director and Chief Executive Officer James Bonnar described the study outcomes as encouraging proof-of-concept data.

According to Bonnar, the results demonstrated a clear additive benefit when Xolatryp was combined with standard-of-care treatment, consistent with enhanced anti-tumour activity of doxorubicin when used alongside the company’s lead candidate.

Management indicated that the findings support the potential for Xolatryp to improve therapeutic outcomes in patients treated with anthracycline-based cancer therapies.

About Xolatryp and Nyrada

Nyrada is a clinical-stage biotechnology company focused on developing small-molecule therapies targeting Transient Receptor Potential Canonical (TRPC) ion channels.

The company’s lead candidate, Xolatryp, is designed to inhibit TRPC3/6/7 channels and limit excessive calcium entry associated with multiple disease pathways.

Beyond oncology, the drug candidate has also been studied in cardioprotection and neuroprotection settings.

Nyrada previously completed a Phase I clinical trial assessing safety, tolerability and pharmacokinetics for Xolatryp.

The company also confirmed that a Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing myocardial ischemia reperfusion injury in STEMI patients undergoing PCI procedures.

As a clinical-stage biotechnology company, Nyrada remains focused on expanding the potential applications of its TRPC ion channel platform across multiple therapeutic areas.

What This Means for Investors

Today’s share price rally suggests investors responded positively to the company’s latest oncology study update and the broader implications for Xolatryp’s commercial potential.

The data demonstrated that Xolatryp not only showed anti-tumour activity independently, but also enhanced the anti-tumour efficacy of doxorubicin in the liver cancer model used in the study.

The provisional oncology patent filing, combined with plans for further preclinical studies, also indicates that Nyrada is continuing to broaden the strategic development pathway for its lead candidate.

While the results remain preclinical and additional studies are still required, investors are likely to continue monitoring future oncology-related developments alongside the company’s ongoing cardiovascular clinical program.